twist shRNA Plasmid (h) from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

twist shRNA Plasmid (h)

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
twist shRNA Plasmid (h)

Product Specs
Itemtwist shRNA Plasmid (h)
CompanySanta Cruz Biotechnology, Inc.
Price $592.00Supplier Page View Company Product Page
Catalog Numbersc-38604-SH
Quantity20 µg
RNA TypeshRNA Clones
Vector Type (Standardized)Lentiviral
TypeshRNA Plasmid
Specieshuman
NCBI Full Gene Nametwist family bHLH transcription factor 1
NCBI Gene AliasesACS3, BPES2, BPES3, CRS, CRS1, CSO, SCS, SWCOS, TWIST, bHLHa38

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis PathwayInternational journal of molecular sciencesApril 10, 2021Bahar E, Kim JY, Kim DC, Kim HS, Yoon H.

(2) Retinoblastoma cell-derived Twist protein promotes regulatory T cell developmentCancer immunology, immunotherapy : CIIApril 1, 2021Zhang R, Song YN, Duo X, Guo Z, Sun Y, Zhang Z, Lu Y, Miao B, Yang PC, Nie G.

(3) Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist ExpressionInternational journal of molecular sciencesOctober 15, 2020Bahar E, Kim JY, Kim HS, Yoon H.

(4) Inhibition of Migration, Invasion and Drug Resistance of Pancreatic Adenocarcinoma Cells - Role of Snail, Slug and Twist and Small Molecule InhibitorsOncoTargets and therapyJanuary 1, 2020Kaşıkcı E, Aydemir E, Bayrak ÖF, Şahin F.

(5) MiR-15a-3p suppresses the growth and metastasis of ovarian cancer cell by targeting Twist1European review for medical and pharmacological sciencesMarch 1, 2019Fan B, Chen LP, Yuan YH, Xiao HN, Lv XS, Xia ZY.

(6) MicroRNA-145 Inhibits Cell Migration and Invasion in Colorectal Cancer by Targeting TWISTOncoTargets and therapyJanuary 1, 2019Shen X, Jiang H, Chen Z, Lu B, Zhu Y, Mao J, Chai K, Chen W.

(7) FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transitionInternational journal of oncologyMay 1, 2018Zhang Y, Lu Y, Zhang C, Huang D, Wu W, Zhang Y, Shen J, Cai Y, Chen W, Yao W.

(8) TMPRSS4 Upregulates TWIST1 Expression through STAT3 Activation to Induce Prostate Cancer Cell MigrationPathology oncology research : PORApril 1, 2018Jianwei Z, Qi L, Quanquan X, Tianen W, Qingwei W.

(9) Inhibition of N-acetyltransferase 10 using remodelin attenuates doxorubicin resistance by reversing the epithelial-mesenchymal transition in breast cancerAmerican journal of translational researchJanuary 1, 2018Wu J, Zhu H, Wu J, Chen W, Guan X.

(10) The effect of TWIST silencing in metastatic chordoma cellsTurkish journal of biology = Turk biyoloji dergisiJanuary 1, 2018Aydemir E, Kaşikci E, Coşkunçelebi B, Bayrak ÖF, Şahin F.

(11) Eukaryotic translation initiation factor 5A-2 involves in doxorubicin-induced epithelial-mesenchymal transition in oral squamous cell carcinoma cellsJournal of CancerJanuary 1, 2018Fang L, Gao L, Xie L, Xiao G.

(12) Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expressionInternational journal of cancerDecember 1, 2017Wu YH, Huang YF, Chang TH, Chou CY.

(13) DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transitionOncotargetNovember 7, 2017Kang X, Li M, Zhu H, Lu X, Miao J, Du S, Xia X, Guan W.

(14) Twist1 confers multidrug resistance in colon cancer through upregulation of ATP-binding cassette transportersOncotargetAugust 8, 2017Liu YR, Liang L, Zhao JM, Zhang Y, Zhang M, Zhong WL, Zhang Q, Wei JJ, Li M, Yuan J, et al.

(15) microRNA-335 inhibits colorectal cancer HCT116 cells growth and epithelial-mesenchymal transition (EMT) process by targeting Twist1Die PharmazieAugust 1, 2017Wang J, Wang X, Liu F, Fu Y.

(16) Inhibition of AMPK-related kinase 5 (ARK5) enhances cisplatin cytotoxicity in non-small cell lung cancer cells through regulation of epithelial-mesenchymal transitionAmerican journal of translational researchJanuary 1, 2017Li M, Zheng C, Xu H, He W, Ruan Y, Ma J, Zheng J, Ye C, Li W.

(17) IL-1β promotes proliferation and migration of gallbladder cancer cells via Twist activationOncology lettersDecember 1, 2016Guo R, Qin Y, Shi P, Xie J, Chou M, Chen Y.

(18) CXCL12/CXCR4 Axis Upregulates Twist to Induce EMT in Human GlioblastomaMolecular neurobiologyAugust 1, 2016Yao C, Li P, Song H, Song F, Qu Y, Ma X, Shi R, Wu J.

(19) MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasisOncotargetJune 21, 2016Yang Z, Xu S, Jin P, Yang X, Li X, Wan D, Zhang T, Long S, Wei X, Chen G, et al.

(20) Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen speciesOncotargetApril 26, 2016Liu RR, Lv YS, Tang YX, Wang YF, Chen XL, Zheng XX, Xie SZ, Cai Y, Yu J, Zhang XN.

Be the First to Write a Review!